Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients.
Stephens
J
J
Transplantation Service, Baylor University Medical Center, Dallas, Texas 75246.
Goldstein
R
R
Crippin
J
J
Husberg
B
B
Holman
M
M
Gonwa
T A
TA
Klintmalm
G
G
D001379:Azathioprine / Q000627:therapeutic use; D015209:Cholangitis, Sclerosing / Q000150:complications / Q000601:surgery*; D003093:Colitis, Ulcerative / Q000150:complications / Q000503:physiopathology; D003424:Crohn Disease / Q000150:complications / Q000503:physiopathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000503:physiopathology*; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D003520:Cyclophosphamide; D001379:Azathioprine; D016559:Tacrolimus